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Abstract
Sympathetic ganglion block (SGB) or intravenous regional block (IVRB) has been recommended for pain management in patients 
with complex regional pain syndrome type I (CRPS-I). Forty-five patients were initially selected but only 43 were accepted for 
the study. The present study evaluated the efficacy of IVRB produced by combining 70 mg lidocaine with 30 µg clonidine (14 
patients, 1 male/13 females, age range: 27-50 years) versus SGB produced by the injection of 70 mg lidocaine alone (14 patients, 
1 male/13 females, age range: 27-54 years) or combined with 30 µg clonidine (15 patients, 1 male/14 females, age range: 25-50 
years) into the stellate ganglion for pain management in patients with upper extremity CRPS-I. Each procedure was repeated 
five times at 7-day intervals, and pain intensity and duration were measured using a visual analog scale immediately before each 
procedure. A progressive and significant reduction in pain scores and a significant increase in the duration of analgesia were 
observed in all groups following the first three blocks, but no further improvement was obtained following the last two blocks. 
Drowsiness, the most frequent side effect, and dry mouth occurred only in patients submitted to SGB with lidocaine combined 
with clonidine. The three methods were similar regarding changes in pain intensity and duration of analgesia. However, IVRB 
seems to be preferable to SGB due to its easier execution and lower risk of undesirable effects. 
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Complex regional pain syndrome type I (CRPS-I), formerly 
known as reflex sympathetic dystrophy (RSD) is defined as “a 
syndrome that usually develops after an initiating noxious event, 
is not limited to the distribution of a single peripheral nerve, and 
is apparently disproportionate to the initiating event” (1).
Guidelines for pharmacological pain management of 
CRPS-I patients include oral use of tricyclic antidepressants, 
gabapentin, opioids, calcitonin, steroids, anticonvulsants, or 
antioxidants, most of which of limited efficacy (2). With persistent 
symptoms, sympathetic ganglion (SGB) or intravenous regional 
(IVRB) block may be recommended (2).
For several years SGB with a local anesthetic was con-
sidered to be a diagnostic test for the identification of CRPS-I 
patients, and the first choice for their management (3). A 
review of randomized controlled trials concluded that there is 
limited to no evidence that sympathetic blocks are effective in 
the treatment of CRPS-I (4). Nevertheless, SGB seems to be 
an effective approach for patients with CRPS-I (5-7), mainly 
when the procedure is initiated within 12 weeks of the onset 
of symptoms (8). 
Intravenous regional anesthesia is considered to be a safe 
and effective way to provide anesthesia for short-duration hand 
surgery (9), and it can also contribute to the management of 
CRPS-I (10). However, the first publication on the usefulness of 
intravenous regional anesthesia for this purpose used guanethi-
dine and was reported as IVRB (11). Conversely, IVRB with 
guanethidine in a trial of 57 CRPS-I patients was associated 
with more pain and vasomotor instability after 6 months (12). 
Other alternatives included IVRB with phentolamine, phenylepi-
nephrine, reserpine, droperidol, or ketanserin but these agents 
were not more effective than a placebo (13).
IVRB with lidocaine alone failed to provide pain relief in 
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CRPS-I patients beyond the duration of the block (14). Intra-
venous lidocaine was superior to a placebo in 16 patients with 
allodynia, but alleviation of spontaneous pain was achieved 
only with the highest dosage (3 g/mL) and for a brief period of 
time (15). More recently, there was a report of a case of CRPS-I 
successfully treated with intravenous lidocaine alone (16). 
Lidocaine combined with methylprednisolone has also 
been described for the treatment of post-traumatic dystrophy 
(17). In another randomized controlled trial, IVRB with meth-
ylprednisolone and lidocaine was not better than placebo in 
alleviating symptoms of CRPS-I (18). The combination of 
a local anesthetic with guanethidine, reserpine, bretylium, 
steroid, or ketorolac has been used for such purpose as well 
(14,17,19,20). The addition of the α2-adrenergic agonist cloni-
dine to lidocaine for intravenous regional anesthesia improved 
postoperative analgesia (9,21) and produced complete pain 
relief in 5 of 7 patients with a diagnosis of CRPS-I of the knee 
(22). Successful treatment of RSD by IVRB with lidocaine and 
clonidine has been reported (23,24). In our university hospital, 
IVRB with clonidine plus lidocaine has been routinely used for 
the management of CRPS-I (25). In contrast, the efficacy of 
lidocaine-induced SGB when combined with clonidine has not 
yet been reported. 
The objective of the present study was to compare the ef-
ficacy of IVRB produced by combining lidocaine with clonidine, 
to that of SGB produced by the injection of lidocaine, alone 
or combined with clonidine, into the stellate ganglion, for the 
management of pain in patients with upper extremity CRPS-I. 
We found that the three procedures were equivalent in reducing 
pain intensity and increasing the duration of analgesia. 
Material and Methods
The study was conducted on 45 outpatients referred to 
the Clinic for Pain Management of Hospital das Clínicas da 
Faculdade de Medicina de Ribeirão Preto. All patients had a 
diagnosis of upper extremity CRPS-I as established by the 
International Association for the Study of Pain (IASP) (1). After 
approval by the Committee on Human Research of the Uni-
versity Hospital, Faculty of Medicine of Ribeirão Preto, written 
informed consent was obtained from all patients before any 
procedural intervention. Utilization of placebo was not permitted 
by our institutional committee. All patients were evaluated at 
the first consultation regarding pain characteristics (localization, 
intensity, duration, quality, and irradiation) and skin temperature, 
and randomly assigned to one of three experimental groups of 
15 patients each. They all reported unsuccessful use of tricyclic 
antidepressants, gabapentin, opioids, or anticonvulsants. At 
admission all patients declared to be free of drugs. 
The second consultation was done 1 week later, when the 
patient was submitted to SGB with 70 mg 1% lidocaine (Xyles-
tesin®) alone in group I (G-I) or combined with 30 µg clonidine in 
group II (G-II), or IVRB with 70 mg 1% lidocaine combined with 
30 µg clonidine in group III (G-III). The drugs were purchased 
from Cristália Produtos Químicos e Farmacêuticos, Brazil, and 
the doses of lidocaine (26) and clonidine (21,27) were within the 
range used in similar situations. The procedure was repeated 
once a week on four occasions. On all occasions, the intensity 
of pain was evaluated immediately before and soon after the 
end of each procedure using a 0-10-cm visual analog scale 
(VAS: 0 = “no pain” and 10 = “worst pain imaginable”). One 
week after the last procedure, the intensity of pain was evalu-
ated once again. After the end of each procedure, the patient 
remained in bed for up to 90 min to allow observation of any 
side effect due to block. Whatever the experimental group, 
blood pressure and heart rate were continuously recorded 
using a monitor apparatus (Dixtal Biomedica, Brazil), starting 
15 min before and then up to 90 min after the SGB or IVRB 
procedure. During the blocking procedure, O2 saturation was 
also continuously monitored using the same apparatus. The 
difference (∆) between the pain score obtained immediately 
before (iVAS) and after (fVAS) was calculated for each patient. 
A significant pain relief occurred whenever fVAS ≤ iVAS/2 and 
∆ ≥3 were reported by the patient as suggested elsewhere 
(28). The patient was then asked to score pain intensity daily 
and record the time when VAS ≥3 was perceived. The interval 
between this time and the end of each procedure was taken 
as the duration of analgesia. 
A fluoroscopy-guided SGB was performed using the 
anterior paratracheal approach on the cervical sympathetic 
chain to reach the stellate ganglion under fluoroscopic view 
(29,30). The skin temperature of the volar aspect of both hands 
under resting conditions was measured at room temperature 
(22 ± 2°C) before and after each blocking procedure using an 
electronic thermometer (Dixtal Biomedica). A 7.0-mL solution 
containing 70 mg 1% lidocaine alone (G-I) or combined with 
1 µg/kg clonidine (G-II) was used. A test volume of 0.5 to 1.0 
mL was initially injected to exclude intravascular positioning, 
and the remaining volume was then administered. An increase 
of at least 2.2°C in the skin temperature of the affected limb 
over the temperature recorded before SGB was considered to 
be a successful block (30). The presence of Horner syndrome 
following SGB was not considered mandatory (5,31). 
IVRB was performed in patients of G-III as described 
elsewhere (32). A vein of the affected extremity was punc-
tured, and the affected arm was exsanguinated by elevating 
its extremity for 1-2 min and wrapping it with an Esmarch 
bandage. A double tourniquet was then positioned around 
the upper affected arm and inflated to 50 mmHg above the 
patient’s systolic blood pressure. The bandages were then 
unwound and the arm was positioned horizontally. A 7.0-mL 
solution containing 1% lidocaine with 1 µg/kg clonidine was 
slowly injected through the punctured vein, and the tourniquet 
pressure was released 30 min later.
Patients were not included in the study if they had a 
history of cardiovascular disease, coagulopathy, neurologic 
degenerative disease or signs of sensory deficit caused by 
somatic peripheral block, cancer or diabetes, or were taking 
a monoaminoxidase inhibitor or an adrenergic or calcium an-
tagonist. Patients were excluded from the study when a sign 
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of hypersensitivity to lidocaine or clonidine was noticed or the 
total number of programmed blocks was not completed.
All procedures were conducted by one of the authors 
(MSDN). Side effects and effectiveness of treatment were 
recorded by another author (JGK) who was 
unaware of the procedure. The number of 15 pa-
tients per group was based on preliminary groups 
showing that the standard deviation of the mean 
VAS was less than 2. For a standard deviation of 
2, a sample size of 12 in each group has a 95% 
power to detect a difference between means of 
3.09 with a level of significance (α) of 0.05 (two-
tailed), as determined using GraphPad StatMate 
2 for Windows (GraphPad software, USA). The 
VAS scores reported immediately before each 
procedure and 1 week after the last procedure, 
and the duration of analgesia are shown as me-
dians and interquartile ranges. The experimental 
groups were compared regarding VAS scores 
and duration of analgesia using the Kruskal-Wallis 
test. Post hoc comparisons were made using the 
Mann-Whitney U-test for differences between 
groups whenever the Kruskal-Wallis statistic was 
significant. Demographic data (age and gender) 
and temperature difference between left and right 
arms were compared by ANOVA followed by the 
Dunnett test. The level of significance was set at 
P < 0.05 in all cases. 
Results
Two patients were excluded from the study 
due to an allergic reaction to lidocaine (one case 
in G-III) and an incomplete number of programmed 
blocks (one case in G-I). The demographic vari-
ables of the groups are shown in Table 1. There 
were no differences between groups regarding 
age, gender distribution or difference in skin 
temperature between the affected and the con-
tralateral arm. The mean age of the patients was 
38 years (range: 25-54 years), and most of them 
were women (93%). The most frequent causes 
of CRPS-I were repetitive strain injury (~42%), 
carpal tunnel syndrome (~26%), late post-surgical 
pain (~19%), and fracture followed by long-lasting 
immobilization (~7%). Pain was more frequent in 
the right (~65%) than in the left arm. All patients 
fulfilled IASP criteria for CRPS-I diagnosis (1): they 
all had continuous pain that was accompanied by 
allodynia in 18 patients or hyperalgesia in 31 
patients, reduced hand strength, skin discolor-
ation, and changes in temperature perception. 
The signs and symptoms observed in the first 
consultation are also shown in Table 2. Edema 
(39 patients), tremors (28 cases) and sudomotor 
changes (25 cases) were frequently reported, but confirmed 
during clinical examination in only 23, 13, and 20 patients, 
respectively. The skin temperature in the affected arm was 
lower than in the contralateral arm in 36 patients. In contrast, 
Table 1. Demographic characteristics of the experimental groups.
G-I G-II G-III
Gender (male/female) 1/13 1/14 1/13
Age range (years) 27-54 25-50 27-50
Mean ± SEM 37.7 ± 7.7 38.6 ± 7.0    39 ± 6.2
Affected arm (right/left) 9/5 10/5 9/5
Causes
Repetitive strain injury 6 6 6
Carpal tunnel syndrome 2 4 5
Late post-surgical pain 4 2 2
Fracture + long-lasting immobilization 2 1 0
Stab wound 0 1 1
Unknown origin 0 1 0
Disease duration range (months) 3-72 8-72 2-48
Mean ± SEM 24.2 ± 4.9 24.2 ± 4.2 22.3 ± 3.4
G-I = patients scheduled for stellate ganglion block with 70 mg lidocaine; G-II 
= patients scheduled for stellate ganglion block with 70 mg lidocaine + 30 µg 
clonidine; G-III = patients scheduled for intravenous regional block with 70 mg 
lidocaine + 30 µg clonidine.
Table 2. Signs and symptoms at the first consultation.
G-I G-II G-III
Symptoms
Continuous pain 14 15 14
Reduced hand strength 14 15 14
Skin discoloration 14 15 14
Perception of temperature change 14 15 14
Edema 11 14 14
Sudomotor changes 3 12 10
Tremors 14 6 8
Signs
Allodynia 4 7 7
Hyperalgesia 9 13 9
Skin blood flow changes 7 9 8
Increased sudoresis 2 7 7
Reduced sudoresis 1 1 2
Edema 7 7 9
Tremors 4 6 3
Trophic changes 7 11 11
Reduced hand grip strength 14 12 12
Mean (± SEM) temperature differencea -2.1 ± 0.4 -2.5 ± 0.3 -1.7 ± 0.4
Data are reported as number of patients. aDifference in skin temperature (°C) 
between the affected arm and contralateral arm. G-I, G-II and G-III are identi-
fied in the legend to Table 1.
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the skin temperature in the affected arm was higher than 
in the contralateral arm in 2 patients.
The groups did not differ significantly (F2,44 = 1.28; P = 
0.22) regarding VAS values reported in the first consultation 
immediately before each procedure (mean ± SEM: G-I = 
8.7 ± 0.3; G-II = 7.9 ± 0.4; G-III = 8.3 ± 0.3). All patients had 
a significant reduction in VAS soon after the end of each 
procedure, but effective pain relief lasted less than 1 week in 
the majority of cases. The time-course of the VAS reported 
by the patients immediately before each procedure did not 
differ significantly between the experimental groups (χ2 ≤ 
5.52; P ≥ 0.06, Kruskal-Wallis test). The VAS score was 
progressively reduced by all procedures from the first to 
the third block, but the remaining blocks did not produce a 
further decrease in VAS score (Figure 1A). The groups also 
did not differ concerning the duration of analgesia reported 
after each procedure (χ2 ≤ 5.32; P ≥ 0.069, Kruskal-Wallis 
test). Effective pain relief lasted progressively longer after 
the first to the third block, but the remaining blocks did not 
produce a further increase in the duration of analgesia 
(Figure 1B). The fVAS reported by the patients soon after 
the end of each procedure is shown in Figure 1C.
Slight and nonsignificant changes in blood pressure 
and heart rate occurred in all groups regarding records 
obtained 15 min before and 90 min after each procedure 
(data not shown). The side effects observed in each group 
are summarized in Table 3. Drowsiness, the most frequent 
side effect, and dry mouth occurred only in patients submit-
ted to SGB with lidocaine combined with clonidine. Less 
frequent side effects were nausea, dizziness, hoarseness, 
and pain at the puncture site.
Discussion
All patients selected for this study fulfilled IASP criteria for 
the diagnosis of CRPS-I, i.e., they had: 1) continuous pain, 
allodynia, or hyperalgesia disproportionate to the injury; 2) 
evidence at some time of edema, changes in skin blood 
flow, or abnormal sudomotor activity in the region of pain, 
and 3) no other conditions that would otherwise account 
Figure 1. Time course of the changes in pain intensity (A) and 
duration of analgesia (B) of patients with upper extremity com-
plex regional pain syndrome type I submitted to stellate ganglion 
block with 70 mg lidocaine alone (G-I, N = 14) or with 30 µg clo-
nidine (G-II, N = 15), or intravenous regional block with lidocaine 
combined with clonidine (G-III, N = 14). Each procedure was per-
formed at the times indicated by the arrows. Pain intensity was 
assessed using a visual analog scale (VAS). Points are medians 
and interquartile ranges. The pain scores achieved soon after 
each procedure (fVAS) are shown in Figure C.
Table 3. Number of patients reporting side effects within 90 min 
following the analgesic procedure.
G-I G-II G-III
Drowsiness 0 14 6
Nausea 1  0 0
Dizziness 2  2 1
Hoarseness 1  2 0
Pain at the site of injection 1  1 0
Dry mouth 0  4 0
G-I, G-II and G-III are identified in the legend to Table 1.
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